APEIRON to Present at the Biotech Showcase Annual Conference on January 9, 2018

VIENNA, Austria, Jan. 05, 2018 (GLOBE NEWSWIRE) -- APEIRON Biologics AG, a company focused on cancer immunotherapy, today announced that it will present at Biotech Showcase™ 2018, to be held January 8–10 at the Hilton San Francisco Union Square during one of the most important weeks in healthcare investing.

APEIRON Biologics AG will present at the Biotech Showcase™ as follows:
Date: Tuesday, January 9, 2018
Time: 1:45 p.m. (PST)
Room: Franciscan D, Ballroom Level
Venue: Hilton San Francisco Union Square Hotel, 333 O’Farrell Street, San Francisco, CA (United States)

In San Francisco, management will conduct a large number of meetings with healthcare investors. If you would like to schedule a meeting, please feel free to reach out to one of the contacts listed at the end of this press release.

About APEIRON Biologics AG
Apeiron is a private biotech company based in Vienna, Austria, engaged in innovative projects in immuno-oncology. Recently, the most advanced program, an antibody-based immunotherapy to treat neuroblastoma, was granted marketing approval in the EU. The company is developing additional immunotherapies, predominantly in clinical stage, based either on targeted, tumor-specific approaches or on the stimulation of the immune system via novel and proprietary modes of action (unique checkpoint blockade mechanisms) to fight cancer by engaging the human body’s natural defense mechanisms. For additional information please go to www.apeiron-biologics.com and follow us on Twitter @apeironbio.

For further information please contact:

APEIRON Biologics AG
Peter Llewellyn-Davies, CFO/CBO
Email: investors@apeiron-biologics.com 

Investor Relations
LifeSci Advisors, LLC 
Chris Maggos
T +1 (646) 597 6989
Email: Chris@LifeSciAdvisors.com

Media Relations international
MC Services AG
Dr. Claudia Gutjahr-Loeser
T +49 89 210 228 0
Email: apeiron@mc-services.eu

Media Relations Austria:
PR&D - Public Relations for Research & Education
T +43 1 505 70 44
Email: contact@prd.at

Back to news